Invasive and non-invasive diagnosis of cirrhosis and portal hypertension

Table 1 Diagnostic performance of serum biomarkers of fibrosis for significant fibrosis (F ≥ 2) and cirrhosis (F4) in patients With hepatitis B or C

Biomarkers	Component	Etiologies	Patients (n)	F ≥ 2 (%)	F4 (%)	AUROC ≥ F2	AUROC F4
FibroTest[52]	GGT, haptoglobin, bilirubin,	HCV	339	80	-	0.87	-
	apolipoprotein A1, alpha-2-macroglobulin
Forns Index[162]	Age, GGT, cholesterol, platelets	HCV	476	26		0.81	-
APRI[53]	AST, platelets	HCV	270	50	17	0.80	0.89
ELF[56]	N-terminal propeptide of collagen type III,	Mixed	1021/4961	40	12	0.78	0.89
	hyaluronic acid, TIMP-1, age
Hepascore[163]	Age, sex, alpha-2-macroglobulin,	HCV	211	57	16	0.82	0.89
	hyaluronate, bilirubin, GGT
Fibrometer[164]	Platelets, prothrombin time, macroglobulin,	Mixed	598/5032	56	37	0.89	0.81
	AST, hyaluronate, age, urea
FIB-4[165]	Age, ALT, AST, platelets	HCV	847	-	17	-	0.85
Fibroscan[110]		HCV	183	74	25	0.83	0.95
Fibroscan[115]		HBV	173	50	8	0.81	0.93
ARFI imaging[134]		Mixed	146/871	48	16	0.89	0.979
MRE[161]		Mixed				0.98	0.99

¹Number of HCV patients;

²Number of patients with viral hepatitis. AUROC: Area under ROC curve; CC: Correctly classified: true positive and negative; HBV: Chronic hepatitis B; HCV: Chronic hepatitis C; NA: Not available; Se: Sensitivity; Sp: Specificity.